GMGarrett D. McPheron

Garrett D. McPheron

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Garrett D. McPheron has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Christian Saporito-Magriña

    Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Ciencias Químicas, Cátedra de Química General e Inorgánica, Buenos Aires, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas, Instituto de Bioquímica y Medicina Molecular Prof. Alberto Boveris (IBIMOL, UBA-CONICET), Buenos Aires, Argentina

    1 shared publication
  • Colette Li

    Department of Biomedical Engineering, Carnegie Mellon University, Pittsburgh, USA

    1 shared publication
  • Colin K. W. Lim

    Department of Bioengineering, University of Illinois, Urbana, IL 61801, USA

    1 shared publication
  • David Brenes

    Stanford University

    1 shared publication
  • Drew L. Sellers

    Department of Bioengineering, University of Washington, Seattle, Washington 98195, United States

    1 shared publication
  • Elizabeth Wayne

    Department of Bioengineering, University of Washington, Seattle, WA, 98195-5061, USA; Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA, 98195-5061, USA

    1 shared publication

Latest Publications

  • Open Access

    Quantitative Analysis of Monocyte-Derived Macrophage NFκB Signaling in Cancer Co-culture Models Using Luciferase-Based Biosensing

    by Colette Li, Megha Anand, Garrett McPheron, Maeve Stiles, Elizabeth Wayne

    Background and Purpose In this study, we investigate the plasticity of tumor-associated macrophages, which originate from circulating monocytes and are associated with poor cancer prognosis. The differentiation of monocytes into macrophages is a dynamic and spatiotemporal process, as is the resulting macrophages’ polarization. However, traditional methods for measuring polarization, such as qPCR and flow cytometry, provide only static information about polarization. To supplement these methods, we present a novel bioluminescent method that allows for time-resolved measurement of NFκB activation in macrophages while in co-culture with cancer cells. By using a monocyte cell line whose NFκB responsive element is labeled with firefly luciferase, we obtain a quantitative and temporal characterization of macrophage polarization in response to tumor-derived signals. Materials and Methods To quantify the effect of tumor cell signaling THP-1 monocytes encoded with a firefly luciferase NFκB response element were co-cultured with cancer cells. We investigated the impact of the following factors on NFκB signaling cancer cell type (HCT116 or MDA-MB-231), ratio of the number of cancer cells to macrophages in co-culture, and the THP-1 cell differentiation state (monocyte or monocyte-derived macrophage). Bioluminescence was measured over three days. Descriptive features of the bioluminescence response curves were then extracted to compare effects between cancer types. Results We observed that the MDA-MB-231 cancer cells induced lower but more persistent NFκB activation in THP-1 monocyte-derived macrophages than was observed in HCT116 co-culture. Higher number of cancer cells (lower macrophage ratio) elicited higher AUC values in HCT116 co-culture compared to low cancer cell conditions. There was no difference between high and low macrophage ratios within the MDA-MB-231 co-culture condition. Moreover, the addition of macrophage differentiation stimuli modulated the NFκB profile in the co-culture. PMA-differentiated macrophages expressed higher and faster peaks of NFκB activation. Conclusion Cancer cells can modulate monocyte/macrophage NFκB transcriptional activity, impacting the overall tumor microenvironment. Using NFκB reporter cells, we found that HCT116 colorectal cancer cells induced fast and strong NFκB activation profiles. In contrast, MDA-MB-231 cancer cells elicited lower but more persistent NFκB activation profiles. This study highlights how bioluminescence reporter assays can be used to extract meaningful metrics about monocyte/macrophage behavior during tumor progression. This approach could also be used to understand the crosstalk between cancer cells and monocytes/macrophages that could be useful in a therapeutic of diagnostic context. Graphical Abstract


  • Open Access

    Delivery of a fibrin-binding hemostatic polymer ameliorates neurovascular damage and neural tissue loss after traumatic brain injury

    by Qinghua Han, David Brenes, Kevin W. Bishop, Trey J. Pichon, Melissa Ling, Garrett D. McPheron, Nathan J. White, Suzie H. Pun, Jonathan T. C. Liu, Drew L. Sellers

    Traumatic brain injury (TBI) often induces blood leakage into brain tissues, which causes further tissue loss after the initial injury. To mitigate this secondary injury, we hypothesized that delivery of a fibrin-binding hemostatic polymer, PolySTAT, would act as a molecular patch and ameliorate brain vessel damage following TBI. We developed a three-dimensional (3D) pathology and analysis workflow to quantify the effects of PolySTAT versus a control polymer, PolySCRM, on neurovascular networks and neural tissue in whole mouse brains. Using a panel of fluorescent probes, our 3D pathology pipeline revealed that PolySTAT treatment preserves neurovascular density and function, reduces hypoxia and blood extravasation, and reduces brain tissue loss after TBI. To further corroborate the 3D microscopy–based findings, gene expression analyses show that PolySTAT attenuates the expression of inflammation and reactive gliosis biomarkers. These findings support future translational investigation of intravenous PolySTAT as an early post-injury therapy to mitigate neural tissue loss after TBI.


  • Open Access

    Targeted gene silencing in the nervous system with CRISPR-Cas13

    by Jackson E. Powell, Colin K. W. Lim, Ramya Krishnan, Tristan X. McCallister, Christian Saporito-Magriña, Maria A. Zeballos, Garrett D. McPheron, Thomas Gaj

    Cas13 nucleases are a class of programmable RNA-targeting CRISPR effector proteins that are capable of silencing target gene expression in mammalian cells. Here, we demonstrate that RfxCas13d, a Cas13 ortholog with favorable characteristics to other family members, can be delivered to the mouse spinal cord and brain to silence neurodegeneration-associated genes. Intrathecally delivering an adeno-associated virus vector encoding an RfxCas13d variant programmed to target superoxide dismutase 1 (SOD1), a protein whose mutation can cause amyotrophic lateral sclerosis, reduced SOD1 mRNA and protein in the spinal cord by >50% and improved outcomes in a mouse model of the disorder. We further show that intrastriatally delivering an RfxCas13d variant programmed to target huntingtin (HTT), a protein whose mutation is causative for Huntington’s disease, led to a ~50% reduction in HTT protein in the mouse brain. Our results establish RfxCas13d as a versatile platform for knocking down gene expression in the nervous system.